Healthcare Industry News: Abbott Vascular
News Release - October 17, 2006
Abbott to Present New Data Across Its Vascular Portfolio at TCT 2006Highlights Include Initial Data From World's First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent; Additional Data on XIENCE (TM)V Drug-Eluting Stent System; Carotid Clinical Trial Results; First-time Results from Study Designed to Increase Understanding of Vulnerable Plaque
ABBOTT PARK, Ill., Oct. 17 (HSMN NewsFeed) -- Abbott (NYSE: ABT ) today announced it will unveil data from several studies across its broad vascular portfolio and pipeline at the Cardiovascular Research Foundation's 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, being held Oct. 22 - 27 at the Washington Convention Center in Washington, D.C. Presentations from Abbott will include initial data on ABSORB, the world's first clinical trial of a fully bioabsorbable drug-eluting stent. Additional data will also be provided from SPIRIT II, Abbott's pivotal trial that demonstrated XIENCE (TM)V showed statistically significant superiority to the TAXUS® paclitaxel-eluting coronary stent system with respect to the study's primary endpoint, which was angiographic in-stent late loss at six months.
Additional featured presentations from Abbott at TCT include data from the ZOMAXX I drug-eluting stent trial; the CAPTURE clinical trial, a post-approval study designed to increase clinical understanding of the potential benefits of carotid artery stenting for patients ineligible for or at high risk for surgery; and first-time data from PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree), a study designed to increase clinical understanding of "vulnerable" plaque, lipid-rich coronary plaques that can suddenly rupture and are believed to be the cause of most heart attacks.
The following presentations will take place at TCT 2006:
ZOMAXX I Clinical Trial Data, Monday, Oct. 23, 11 a.m. EST, Main Arena
Bernard Chevalier, M.D., of Centre Cardiologique Nord, near Paris, will present nine-month data from the ZOMAXX I coronary drug-eluting stent clinical trial in the Main Arena of the Washington Convention Center. Abbott recently announced it will focus its commercial, manufacturing and clinical resources on the successful launch of XIENCE V and will not pursue commercialization of ZoMaxx(TM).
ABSORB Clinical Trial Data, Tuesday, Oct. 24, 1:15 p.m. EST, Main Arena
ABSORB is the world's first clinical trial designed to evaluate the safety of a fully bioabsorbable everolimus-eluting coronary stent platform. John Ormiston, M.D., Auckland City Hospital, New Zealand will present 30-day clinical results from the on-going ABSORB trial. A press conference on the ABSORB data will be held for media at 2:48 p.m. EST in the TCT press conference room.
XIENCE V Drug-Eluting Stent Follow-up Data, Wednesday, Oct. 25, 7 p.m. EST (Abbott-sponsored symposium)
Abbott will present follow-up data from its SPIRIT II clinical study, providing a more in-depth look at XIENCE V nine-month clinical results as well as coronary drug-eluting stent performance in a subset analysis of diabetic patients, patients with long atherosclerotic coronary artery lesions and patients with small vessels. Data will be presented by Prof. Patrick W. Serruys, M.D., of the Thoraxcenter, Erasmus University Hospital, Rotterdam, and principal investigator of the SPIRIT II clinical trial.
PROSPECT Vulnerable Plaque Data, Thursday, Oct. 26, 11:39 a.m., Room 202A
First-time baseline demographics and imaging data from PROSPECT will be presented by Gregg W. Stone, M.D. PROSPECT is a landmark study designed to increase clinical understanding of "vulnerable" plaque - a lipid-rich coronary plaque that suddenly ruptures - believed to be the cause of most heart attacks.
In addition to the PROSPECT study, data from a pre-clinical study evaluating several interventional approaches to explore the possibility of stabilizing vulnerable lesions before they rupture will be presented by Pedro R. Moreno, M.D., Fellow of the American College of Cardiology, and K-Raman Purushothaman, M.D. at 4:32 p.m. EST, Thursday, Oct. 26.
Data from a study on the economic viability of vulnerable plaque diagnosis and treatment will be presented by Uwe Siebert, M.D., director of the Cardiovascular Research Program at the Institute for Technology Assessment and associate professor of Radiology at Harvard Medical School at 5:02 p.m. EST, Thursday, Oct. 26.
CAPTURE Carotid Artery Stenting Data, Thursday, Oct. 26, 5:07 p.m. EST, Room 151AB
William A. Gray, M.D., from the Cardiac Research Foundation and Columbia Presbyterian Hospital, will present the results from Abbott's CAPTURE clinical trial. CAPTURE is one of eight clinical trials Abbott currently has under way to advance the understanding of carotid artery stenting for patients with carotid artery disease.
Poster Presentations on the XIENCE V Coronary Drug Eluting Stent System
Patrick W. Serruys, M.D., Ph.D., professor of interventional cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, will present two electronic poster abstracts at TCT. The first abstract is titled "SPIRIT II Clinical Study: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo, Native Coronary Artery Lesions - IVUS Substudy." The second abstract is titled "SPIRIT II Clinical Study: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions." Both abstracts will be available electronically to view and download at kiosk stations throughout the convention center.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety, effectiveness and ease of use in treating patients with vascular disease.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com .
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsFDA Approves Abbott's "Low Dose," Recharge-Free Spinal Cord Stimulation System with up to Ten Year Battery Life* for People Living with Chronic Pain
Abbott Announces European Approval of Two Life-saving Heart Devices for Babies and Children
Abbott's Revolutionary FreeStyle(R) Libre System Now Reimbursed in the Two Largest Provinces in Canada